Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination ophthalmic formulation containing polyethylene glycol 400 (PEG 400), propylene glycol, and hydroxypropyl-guar. It is used as an artificial tear or lubricant eye drop for the temporary relief of burning and irritation due to dry eyes. Polyethylene glycol 400 and propylene glycol act as lubricants that mimic natural tears to moisten the ocular surface and reduce symptoms of dryness[1][2][7]. Hydroxypropyl-guar is a derivative of guar gum that acts as a viscosity-enhancing agent; it forms a gel-like matrix on the eye surface which helps stabilize the tear film and prolongs retention time of the lubricants[6]. The combination restructures and stabilizes all three layers of the tear film (mucin, aqueous, lipid), reduces evaporation/drainage of tears, provides symptomatic relief from environmental or medical causes of dry eye disease[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 400 + propylene glycol + hydroxypropyl-guar.